drugset / Trial / NCT06095115

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115

Phase 3 Active not recruiting 684 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Timeline

Start
2023-10-12
Primary completion
2024-07-29
Completion
2027-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide 200 mg Oral

Indications